Compare WAVE & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | CELU |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Israel | United States |
| Employees | N/A | 123 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 35.2M |
| IPO Year | 2021 | N/A |
| Metric | WAVE | CELU |
|---|---|---|
| Price | $7.07 | $1.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.0K | ★ 99.2K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,913.16 | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.51 | $1.01 |
| 52 Week High | $9.85 | $4.35 |
| Indicator | WAVE | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 48.70 |
| Support Level | $5.72 | $1.21 |
| Resistance Level | $7.11 | $1.38 |
| Average True Range (ATR) | 0.49 | 0.11 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 73.12 | 49.99 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.